{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": [],
      "authorship_tag": "ABX9TyMpSTdAvLHrhMdX767qipyG",
      "include_colab_link": true
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/sg3451/Colab_Notebooks/blob/main/Abstract_summary_ChatGPT.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "Install openai"
      ],
      "metadata": {
        "id": "rsCLo944YD8Z"
      }
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "NhIlEZieX0PK",
        "outputId": "207d32ff-4edc-4787-dcdb-6bef5096692b"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: openai in /usr/local/lib/python3.10/dist-packages (0.28.0)\n",
            "Requirement already satisfied: requests>=2.20 in /usr/local/lib/python3.10/dist-packages (from openai) (2.31.0)\n",
            "Requirement already satisfied: tqdm in /usr/local/lib/python3.10/dist-packages (from openai) (4.66.1)\n",
            "Requirement already satisfied: aiohttp in /usr/local/lib/python3.10/dist-packages (from openai) (3.8.5)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests>=2.20->openai) (3.2.0)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests>=2.20->openai) (3.4)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests>=2.20->openai) (2.0.4)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests>=2.20->openai) (2023.7.22)\n",
            "Requirement already satisfied: attrs>=17.3.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp->openai) (23.1.0)\n",
            "Requirement already satisfied: multidict<7.0,>=4.5 in /usr/local/lib/python3.10/dist-packages (from aiohttp->openai) (6.0.4)\n",
            "Requirement already satisfied: async-timeout<5.0,>=4.0.0a3 in /usr/local/lib/python3.10/dist-packages (from aiohttp->openai) (4.0.3)\n",
            "Requirement already satisfied: yarl<2.0,>=1.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp->openai) (1.9.2)\n",
            "Requirement already satisfied: frozenlist>=1.1.1 in /usr/local/lib/python3.10/dist-packages (from aiohttp->openai) (1.4.0)\n",
            "Requirement already satisfied: aiosignal>=1.1.2 in /usr/local/lib/python3.10/dist-packages (from aiohttp->openai) (1.3.1)\n"
          ]
        }
      ],
      "source": [
        "!pip install openai"
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "import openai"
      ],
      "metadata": {
        "id": "9vPzxC9dX-z_"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "import openai\n",
        "import os\n",
        "openai.api_key = \"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\"\n"
      ],
      "metadata": {
        "id": "rhkpLzv0c409"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "setup how the model returns the result of a prompt"
      ],
      "metadata": {
        "id": "c_3wErW-ZV5k"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "def get_completion(prompt, model=\"gpt-3.5-turbo\"):\n",
        "    messages = [{\"role\": \"user\", \"content\": prompt}]\n",
        "    response = openai.ChatCompletion.create(\n",
        "        model=model,\n",
        "        messages=messages,\n",
        "        temperature=0, # this is the degree of randomness of the model's output\n",
        "    )\n",
        "    return response.choices[0].message[\"content\"]"
      ],
      "metadata": {
        "id": "aDXagBniY6LF"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "replace a word used twice in the same sentence"
      ],
      "metadata": {
        "id": "k7UIN35tZfbH"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "# summarize abstracts from IJO articles from 01/08/2023 to 01/09/2023"
      ],
      "metadata": {
        "id": "wgwVJ_xNocfx"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "abstracts = \"\"\" 1. Int J Obes (Lond). 2023 Aug;47(8):677-685. doi: 10.1038/s41366-023-01321-5. Epub\n",
        "2023 May 31.\n",
        "\n",
        "Efficacy and safety of tirzepatide for treatment of overweight or obesity. A\n",
        "systematic review and meta-analysis.\n",
        "\n",
        "Tan B(#)(1), Pan XH(#)(1), Chew HSJ(2), Goh RSJ(1), Lin C(1), Anand VV(3), Lee\n",
        "ECZ(3), Chan KE(1), Kong G(4), Ong CEY(1), Chung HC(1), Young DY(1), Chan\n",
        "MY(1)(5), Khoo CM(1)(6), Mehta A(7), Muthiah MD(1)(8)(9), Noureddin M(10), Ng\n",
        "CH(11), Chew NWS(1)(5), Chin YH(12).\n",
        "\n",
        "Author information:\n",
        "(1)Yong Loo Lin School of Medicine, National University of Singapore, Singapore,\n",
        "Singapore.\n",
        "(2)Alice Lee Centre for Nursing Studies, Yong Loo Lin School of Medicine,\n",
        "National University of Singapore, Singapore, Singapore.\n",
        "(3)Lee Kong Chian School of Medicine, Nanyang Technological University,\n",
        "Singapore, Singapore.\n",
        "(4)Ministry of Health Holdings, Ministry of Health, Singapore, Singapore.\n",
        "(5)Department of Cardiology, National University Heart Centre, Singapore,\n",
        "Singapore.\n",
        "(6)Department of Endocrinology, National University Hospital, Singapore,\n",
        "Singapore.\n",
        "(7)VCU Health Pauley Heart Center, Division of Cardiology, Department of\n",
        "Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA.\n",
        "(8)Division of Gastroenterology and Hepatology, Department of Medicine, National\n",
        "University Hospital, Singapore, Singapore.\n",
        "(9)National University Centre for Organ Transplantation, National University\n",
        "Health System, Singapore, Singapore.\n",
        "(10)Cedars-Sinai Fatty Liver Program, Division of Digestive and Liver Diseases,\n",
        "Department of Medicine, Comprehensive Transplant Centre, Cedars-Sinai Medical\n",
        "Centre, Los Angeles, CA, USA.\n",
        "(11)Ministry of Health Holdings, Ministry of Health, Singapore, Singapore.\n",
        "chenhanng@gmail.com.\n",
        "(12)Ministry of Health Holdings, Ministry of Health, Singapore, Singapore.\n",
        "yiphan97@gmail.com.\n",
        "(#)Contributed equally\n",
        "\n",
        "BACKGROUND: Recent studies suggest that tirzepatide, a dual glucose-dependent\n",
        "insulinotropic-peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1\n",
        "RA), has significant weight loss effects. This systematic review and\n",
        "meta-analysis aims to assess the efficacy and safety of tirzepatide for weight\n",
        "loss in patients with overweight or obesity.\n",
        "METHODS: Medline, Embase and Cochrane CENTRAL were searched for randomized\n",
        "controlled trials (RCTs) on tirzepatide's weight loss efficacy for these\n",
        "patients. A single arm meta-analysis of proportions estimated primary outcomes,\n",
        "â‰¥5%, â‰¥10%, and â‰¥15% weight loss, and adverse events (AEs); while meta-analysis\n",
        "of means estimated secondary outcomes. Comparative meta-analysis was conducted\n",
        "between tirzepatide and control arms where mean differences and odds ratios were\n",
        "estimated for continuous and dichotomous outcomes respectively.\n",
        "RESULTS: RCTs included in this study revealed that among 5800 patients, 78.22%\n",
        "(95% CI: 72.15% to 83.73%), 55.60% (95% CI: 46.54% to 64.47%), 32.28% (95% CI:\n",
        "23.17% to 42.12%) achieved â‰¥5%, â‰¥10%, and â‰¥15% weight loss, respectively.\n",
        "Tirzepatide 5â€‰mg demonstrated weight loss superiority relative to placebo (MD:\n",
        "-12.47â€‰kg, 95% CI: -13.94â€‰kg to -11.00â€‰kg) and semaglutide (nâ€‰=â€‰1409, MD:\n",
        "-1.90â€‰kg, 95% CI: -2.97â€‰kg to -0.83â€‰kg) with dose-dependent increase for 10â€‰mg\n",
        "and 15â€‰mg doses. The comparison between tirzepatide and semaglutide was examined\n",
        "in the SURPASS-2 trial that was included in this systematic review. For AEs,\n",
        "there was increase odds of experiencing gastrointestinal AEs with tirzepatide\n",
        "compared to placebo, but no significant difference with semaglutide.\n",
        "CONCLUSION: Tirzepatide has significant potential as a weight loss drug in\n",
        "patients with overweight and obesity, with little increase in AEs compared to\n",
        "other weight loss drugs. With its ability to concurrently target multiple\n",
        "aspects of metabolic syndrome, it should be considered as the next helm of\n",
        "weight loss therapies.\n",
        "\n",
        "Â© 2023. The Author(s), under exclusive licence to Springer Nature Limited.\n",
        "\n",
        "DOI: 10.1038/s41366-023-01321-5\n",
        "PMID: 37253796 [Indexed for MEDLINE]\n",
        "\n",
        "\n",
        "2. Int J Obes (Lond). 2023 Aug 18. doi: 10.1038/s41366-023-01365-7. Online ahead of\n",
        "print.\n",
        "\n",
        "Anti-obesity effects of chlorogenic acid and caffeine- lipid nanoparticles\n",
        "through PPAR-Î³/C/EBP-É‘ pathways.\n",
        "\n",
        "Uner B(#)(1), Macit Celebi MS(#)(2).\n",
        "\n",
        "Author information:\n",
        "(1)Department of Pharmaceutical and Administrative Sciences, University of\n",
        "Health Science and Pharmacy in St Louis, St. Louis, MO, USA.\n",
        "burcu.uner@uhsp.edu.\n",
        "(2)Department of Nutrition and Dietetics, Ondokuz Mayis University, Samsun,\n",
        "Turkey.\n",
        "(#)Contributed equally\n",
        "\n",
        "Obesity is considered one of the most crucial health problems of the century.\n",
        "Therefore, reducing obesity is critically important. Caffeine (CF) and\n",
        "chlorogenic acid (CLA), which are substantial components in green bean coffee\n",
        "which maximize thermogenesis in brown adipose tissue. In our study, we have\n",
        "prepared CF, CLA, and CFâ€‰+â€‰CLA loaded-solid lipid nanoparticles (SLN) since the\n",
        "SLNs are cost-effective, tissue-localized, and highly stable. The central\n",
        "composite design model was preferred to select the optimized formulation. UHPLC\n",
        "was used for quantification related to the CF and CLA amounts. The high-pressure\n",
        "homogenization (HPH) method was used while SLN formulations were prepared in the\n",
        "presence of poloxamerÂ® 407 (surfactant) and CompritolÂ® 888 ATO (solid lipid).\n",
        "The nanoparticles were characterized, followed by the utilization of 3T3-F442A\n",
        "cell lines for the evaluation of the adipogenesis activity of the formulations.\n",
        "Then, rt-PCR and ELISA studies of adipogenic markers were conducted. After\n",
        "optimal formulations were selected with an average of 110.2â€‰Â±â€‰0.1â€‰nm, CF\n",
        "(1â€‰mM)â€‰+â€‰CLA (0.5â€‰mM)-loaded SLN formulation has been proven significantly\n",
        "effective by using PPAR-Î³/C/EBP-a pathways. In a nutshell, our study has shown\n",
        "that CFâ€‰+â€‰CLA loaded-SLN has been affected 45.8% times more than regular\n",
        "extracted coffee (pâ€‰<â€‰0.05) on the adipocyte cells.\n",
        "\n",
        "Â© 2023. This is a U.S. Government work and not under copyright protection in the\n",
        "US; foreign copyright protection may apply.\n",
        "\n",
        "DOI: 10.1038/s41366-023-01365-7\n",
        "PMID: 37596386\n",
        "\n",
        "\n",
        "3. Int J Obes (Lond). 2023 Aug 4. doi: 10.1038/s41366-023-01352-y. Online ahead of\n",
        "print.\n",
        "\n",
        "Glucose metabolism disorder: a potential accomplice of SARS-CoV-2.\n",
        "\n",
        "Luan Y(1), Luan Y(2), He H(3), Jue B(4), Yang Y(5), Qin B(6), Ren K(7)(8).\n",
        "\n",
        "Author information:\n",
        "(1)Department of Translational Medicine Center, the First Affiliated Hospital of\n",
        "Zhengzhou University, Zhengzhou, 450052, China.\n",
        "(2)State Key Laboratory for Artificial Microstructures and Mesoscopic Physics,\n",
        "School of Physics, Peking University, Beijing, 100000, China.\n",
        "(3)Department of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou\n",
        "University, Zhengzhou, 450001, China.\n",
        "(4)School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang,\n",
        "453000, China.\n",
        "(5)Department of Translational Medicine Center, the First Affiliated Hospital of\n",
        "Zhengzhou University, Zhengzhou, 450052, China. yangyangbio@163.com.\n",
        "(6)Department of Translational Medicine Center, the First Affiliated Hospital of\n",
        "Zhengzhou University, Zhengzhou, 450052, China. boqin@mail.ustc.edu.cn.\n",
        "(7)Department of Pharmacy, the First Affiliated Hospital of Zhengzhou\n",
        "University, Zhengzhou, 450052, China. renkd006@163.com.\n",
        "(8)Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University,\n",
        "Zhengzhou, 450052, China. renkd006@163.com.\n",
        "\n",
        "Globally, 265,713,467 confirmed cases of SARS-CoV-2 (CoV-2), including 5,260,888\n",
        "deaths, have been reported by the WHO. It is important to study the mechanism of\n",
        "this infectious disease. A variety of evidences show the potential association\n",
        "between CoV-2 and glucose metabolism. Notably, people with type 2 diabetes\n",
        "mellitus (T2DM) and other metabolic complications were prone to have a higher\n",
        "risk of developing a more severe infection course than people who were\n",
        "metabolically normal. The correlations between glucose metabolism and CoV-2\n",
        "progression have been widely revealed. This review will discuss the association\n",
        "between glucose metabolism disorders and CoV-2 progression, showing the\n",
        "promoting effect of diabetes and other diseases related to glucose metabolism\n",
        "disorders on the progression of CoV-2. We will further conclude the effects of\n",
        "key proteins and pathways in glucose metabolism regulation on CoV-2 progression\n",
        "and potential interventions by targeting glucose metabolism disorders for CoV-2\n",
        "treatment. Therefore, this review will provide systematic insight into the\n",
        "treatment of CoV-2 from the perspective of glucose metabolism.\n",
        "\n",
        "Â© 2023. The Author(s), under exclusive licence to Springer Nature Limited.\n",
        "\n",
        "DOI: 10.1038/s41366-023-01352-y\n",
        "PMID: 37542197\n",
        "\n",
        "\n",
        "4. Int J Obes (Lond). 2023 Aug 1. doi: 10.1038/s41366-023-01357-7. Online ahead of\n",
        "print.\n",
        "\n",
        "Vegetarian diets on anthropometric, metabolic and blood pressure outcomes in\n",
        "people with overweight and obesity: a systematic review and meta-analysis of\n",
        "randomized controlled trials.\n",
        "\n",
        "Melgar B(1), Diaz-Arocutipa C(2), Huerta-Rengifo C(3)(4), Piscoya A(2)(5),\n",
        "Barboza JJ(2)(3), Hernandez AV(2)(6).\n",
        "\n",
        "Author information:\n",
        "(1)Unidad de Revisiones SistemÃ¡ticas y Meta-anÃ¡lisis (URSIGET), Vicerrectorado\n",
        "de InvestigaciÃ³n, Universidad San Ignacio de Loyola, Lima, Peru.\n",
        "beamelgar@gmail.com.\n",
        "(2)Unidad de Revisiones SistemÃ¡ticas y Meta-anÃ¡lisis (URSIGET), Vicerrectorado\n",
        "de InvestigaciÃ³n, Universidad San Ignacio de Loyola, Lima, Peru.\n",
        "(3)Tau Relaped Group, Trujillo, Peru.\n",
        "(4)Facultad de Medicina, Universidad Privada Antenor Orrego, Trujillo, Peru.\n",
        "(5)Hospital Guillermo Kaelin de la Fuente, Lima, Peru.\n",
        "(6)Health Outcomes, Policy, and Evidence Synthesis (HOPES) Group, University of\n",
        "Connecticut School of Pharmacy, Storrs, CT, USA.\n",
        "\n",
        "BACKGROUND: It is unknown whether vegetarian diets (VDs) may improve outcomes in\n",
        "people with overweight and obesity.\n",
        "OBJECTIVE: To systematically assess the effects of VDs vs. omnivore diets on\n",
        "anthropometric, metabolic, and blood pressure outcomes in people with overweight\n",
        "and obesity.\n",
        "METHODS: We searched for randomized controlled trials (RCTs) in EMBASE, PubMed,\n",
        "Web of Science, and Scopus until February 2, 2022. Primary outcomes were\n",
        "anthropometric risk factors (weight, body mass index [BMI], waist circumference\n",
        "[WC], hip circumference [HC], and body fat percentage). Secondary outcomes were\n",
        "metabolic risk factors (fasting serum glucose, HbA1c, insulin levels) and blood\n",
        "pressure (systolic blood pressure [SBP], diastolic blood pressure [DBP]).\n",
        "Random-effects meta-analyses were performed and effects were expressed as mean\n",
        "difference (MD) and their 95% confidence intervals (CI). The quality of evidence\n",
        "was assessed using GRADE methods.\n",
        "RESULTS: Nine RCTs (nâ€‰=â€‰1628) were included. VDs decreased weight (MD -3.60â€‰kg,\n",
        "95%CI -4.75 to -2.46) and glucose (MD -10.64â€‰mg/dL, 95%CI -15.77 to -5.51), but\n",
        "did not decrease WC (MD -3.00â€‰cm, 95%CI -6.20 to 0.20), BMI (MD -0.87â€‰kg/m2,\n",
        "95%CI -1.80 to 0.06), or HC (MD: -0.86â€‰cm, 95%CI -3.46 to 1.74). VDs did not\n",
        "decrease HbA1c (MD -0.40%, 95%CI -0.89 to 0.10), insulin (MD -3.83â€‰mU/L, 95%CI\n",
        "-8.06 to 0.40), SBP (MD -0.25â€‰mmHg, 95%CI -2.58 to 2.07), or DBP (MD -1.57â€‰mmHg,\n",
        "95%CI -3.93 to 0.78). Subgroup analyses by type of VD (four RCTs evaluated\n",
        "lacto-ovo-vegetarian diets and five RCTs vegan diets) showed similar results to\n",
        "the main analyses. QoE was very low for most of the outcomes.\n",
        "CONCLUSIONS: In comparison to an omnivorous diet, VDs may reduce weight and\n",
        "glucose, but not blood pressure or other metabolic or anthropometric outcomes.\n",
        "However, the QoE was mostly very low. Larger RCTs are still needed to evaluate\n",
        "the effects of VD on anthropometric, metabolic factors, and blood pressure in\n",
        "people with overweight and obesity.\n",
        "\n",
        "Â© 2023. The Author(s), under exclusive licence to Springer Nature Limited.\n",
        "\n",
        "DOI: 10.1038/s41366-023-01357-7\n",
        "PMID: 37528197\n",
        "\n",
        "\"\"\"\n"
      ],
      "metadata": {
        "id": "zGyugfuSoqt1"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [],
      "metadata": {
        "id": "8FQqdYom7S3y"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "prompt = f\"\"\" You are given some information for some scientific articles.\\\n",
        "The articles are separated by numbers 1, 2, 3, etc.\n",
        "Consider each article separately.\n",
        "For each article summarize the information contained in its abstract \\\n",
        "The abstract usually begins with section named BACKGROUND and will contain \\\n",
        "additional sections such as METHODS, RESULTS and CONCLUSION\n",
        "Sometimes you may find alternative section header names such as AIM or OBJECTIVE\n",
        "If you do not find any of these section headers, report it as \"Section headers missing\"\n",
        "You will also extract the title of each article and the list of authors for each of them\\\n",
        "Express the authors names in \"last name, initials\" format\n",
        "Summarize the abstract in scientific language to no more than 3 sentences for each article\\\n",
        "Return the results in the following format:\n",
        "Title: <title of article>\n",
        "PMID: <Pubmed id of article>\n",
        "Authors: <author names in last name, first initials format>\n",
        "Summary: <summary in bullet point format>\n",
        "\n",
        "Abstracts: ``` {abstracts}```\n",
        "\"\"\"\n",
        "response = get_completion(prompt)\n",
        "print(response)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "A81jSgjrpGrA",
        "outputId": "dc2c0f5b-646e-4188-8952-0c4fd4422bb8"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Title: Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis.\n",
            "PMID: 37253796\n",
            "Authors: Tan B, Pan XH, Chew HSJ, Goh RSJ, Lin C, Anand VV, Lee ECZ, Chan KE, Kong G, Ong CEY, Chung HC, Young DY, Chan MY, Khoo CM, Mehta A, Muthiah MD, Noureddin M, Ng CH, Chew NWS, Chin YH\n",
            "Summary:\n",
            "- Tirzepatide, a dual glucose-dependent insulinotropic-peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA), has significant weight loss effects.\n",
            "- This systematic review and meta-analysis found that tirzepatide demonstrated weight loss superiority compared to placebo and semaglutide, with dose-dependent effects.\n",
            "- Tirzepatide has the potential to be a weight loss drug with little increase in adverse events.\n",
            "\n",
            "Title: Anti-obesity effects of chlorogenic acid and caffeine-lipid nanoparticles through PPAR-Î³/C/EBP-É‘ pathways.\n",
            "PMID: 37596386\n",
            "Authors: Uner B, Macit Celebi MS\n",
            "Summary:\n",
            "- Chlorogenic acid (CLA) and caffeine (CF) in green bean coffee have thermogenic effects in brown adipose tissue.\n",
            "- This study prepared lipid nanoparticles loaded with CF, CLA, and CF+CLA, which were effective in promoting adipogenesis activity through PPAR-Î³/C/EBP-É‘ pathways.\n",
            "- The CF+CLA loaded-solid lipid nanoparticles showed significantly greater effects on adipocyte cells compared to regular extracted coffee.\n",
            "\n",
            "Title: Glucose metabolism disorder: a potential accomplice of SARS-CoV-2.\n",
            "PMID: 37542197\n",
            "Authors: Luan Y, He H, Jue B, Yang Y, Qin B, Ren K\n",
            "Summary:\n",
            "- Glucose metabolism disorders have been associated with the progression of SARS-CoV-2 infection.\n",
            "- People with type 2 diabetes mellitus and other metabolic complications are at a higher risk of developing severe infection.\n",
            "- This review discusses the potential promoting effect of glucose metabolism disorders on the progression of SARS-CoV-2 and the potential interventions targeting glucose metabolism for treatment.\n",
            "\n",
            "Title:\n"
          ]
        }
      ]
    }
  ]
}